On April 2, 2021 NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that it has changed its corporate name to NKGen Biotech, Inc., which the Company believes best reflects its mission and strategic focus (Press release, NKMax America, APR 2, 2021, View Source [SID1234577554]). The name change is effective immediately.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe the name NKGen Biotech more accurately represents the direction our company is headed and our commitment to developing the next generation of natural killer cell immunotherapies with the potential to restore immune function in patients with cancer worldwide," said Stephen Chen, NKGen Biotech Chief Operating Officer and Chief Technical Officer.

Mr. Chen further commented, "Our clinical programs remain on track and we plan to report full data from our Phase 1 monotherapy trial of SNK01 in refractory solid tumors in the second quarter of 2021, while advancing our partnered combination programs with Merck KGaA and Affimed throughout the year. We are excited to embark on the next steps in our journey to become the leading player in NK cell therapeutics."

The Company’s lead drug candidate, SNK01, is an investigational autologous NK cell-based therapy which is currently being studied alone and in combination with other approved drugs for the treatment of cancer. NKGen Biotech also plans to file an IND for its allogeneic NK cell platform in 2022.